ALSN News (online only)

Investigational drug GM604 has shown some intriguing results in a very small number of ALS patients

Posted on Thursday, January 22, 2015 - 10:13, By: Margaret Wahl
Biopharmaceutical company Genervon has announced what it considers encouraging  results from a "compassionate use" trial of its experimental drug GM604 in a single patient with advanced amyotrophic lateral sclerosis (ALS).


Posted on Tuesday, January 13, 2015 - 12:04, By: Margaret Wahl
Update (Feb. 6, 2015): This article has been edited to reflect that patients in the BrainStorm trial in the U.S. will receive injections of NurOwn cells into a muscle and into the spinal fluid simultaneously, at a single point in time.

Stanford University is collecting samples of blood, muscle and other tissues from people with neuromuscular disorders for use in research

Posted on Wednesday, January 7, 2015 - 15:36, By: Margaret Wahl
Ever wondered how someone with a neuromuscular disorder in his or her family might contribute to research efforts in this field?

MDA has joined forces with the ALS Association to fight ALS through a grant to James Shorter at the University of Pennsylvania

Posted on Wednesday, December 3, 2014 - 14:09, By: Margaret Wahl
MDA has joined forces with the ALS Association (ALSA) to fund a new research project aimed at finding a potential therapy for amyotrophic lateral sclerosis (ALS). The two organizations have made a $240,000 award to molecular biologist James Shorter at the Perelman School of Medicine at the University of Pennsylvania. Shorter also has an existing MDA grant for related research.

In a phase 2 trial, the drug mexiletine was found to reduce the frequency of muscle cramps but not to affect motor or respiratory function

Posted on Tuesday, November 25, 2014 - 15:55, By: Margaret Wahl
Preliminary results of a trial of mexiletine in 60 people with amyotrophic lateral sclerosis (ALS) show the drug is reasonably safe and well tolerated and possibly effective for reducing the frequency and intensity of muscle cramps associated with this disorder. However, no benefits were seen in mexiletine recipients versus placebo recipients on tests of motor or respiratory function.

Israeli biotechnology company BrainStorm will test its adult stem cells, derived from bone marrow, in 48 ALS patients at three sites

Posted on Friday, June 13, 2014 - 10:06, By: Margaret Wahl
Israeli biotechnology company BrainStorm Cell Therapeutics has enrolled the first participant in a phase 2, U.S.-based trial of adult stem cell transplantation to treat amyotrophic lateral sclerosis (ALS).